Abstract
AbstractIndividuals who carry BRCA1 or BRCA2 pathogenic variants are recommended to have extensive cancer prevention screening and risk-reducing surgeries. Uptake of these recommendations is variable, and there remains room for improvement in the risk management of BRCA carriers. This paper explores female BRCA carriers’ experiences with the current model of care and their perspectives on (and interest in) an inherited cancer registry. Findings can inform the development of a dedicated high-risk screening and management program for these patients. Quantitative and qualitative data were gathered through a provincial descriptive survey and semi-structured qualitative interviews to assess BRCA carriers’ opinions toward risk management services in the province of Newfoundland and Labrador (NL), Canada. Survey (n = 69) and interview data (n = 15) revealed continuity and coordination challenges with the current system of care of high-risk individuals. Respondents suggested an inherited cancer registry would help identify high-risk individuals and provide a centralized system of risk management for identified carriers. Respondents identified concerns about the privacy of their registry data, including who could access it. Findings suggest BRCA carriers see great value in an inherited cancer registry. Specifically, participants noted it could provide a centralized system to help improve the coordination of burdensome, life-long risk management. Important patient concerns about protecting their privacy and their health data confidentiality must be addressed in patient and public information and informed consent documents about a registry.
Publisher
Springer Science and Business Media LLC
Subject
Genetics (clinical),Public Health, Environmental and Occupational Health,Epidemiology
Reference29 articles.
1. Barrow P, Khan M, Lalloo F, Evans DG, Hill J (2013) Systematic review of the impact of registration and screening on colorectal cancer incidence and mortality in familial adenomatous polyposis and Lynch syndrome. Br J Surg 100(13):1719–1731
2. Buchanan A, Voils C, Schildkraut J et al (2017) Adherence to recommended risk management among unaffected women with a BRCA mutation. J Genet Couns 26(1):79–92
3. Burn J, Sheth H, Elliott E et al (2020) Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10 year follow up and registry-based 20 year data in the CAPP2 study: a double-blind, randomized, placebo-controlled trial. Lancet 395:1855–1863
4. Chafe R (2017) The value of qualitative description in health services and policy research. Health Policy 12(3):12–18
5. Easton DF, Ford D, Bishop DT (1995) Breast and ovarian cancer incidence in BRCA1-mutation carriers. Am J Hum Genet 56(1):265–271
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献